Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (452)
Cancellation by sponsor (239)
Cancellation or suspension (79)
Prescription medicine registration (45)
Cancellation for failure to pay annual charge (17)
Australian public assessment report (AusPar) (5)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2025 (97)
2024 (73)
2023 (99)
2022 (70)
2021 (67)
2020 (112)
2019 (18)
2018 (68)
2017 (104)
2016 (27)
2015 (33)
2014 (13)
2013 (6)
2012 (4)
2011 (6)
2010 (16)
2009 (4)
2008 (3)
2007 (5)
2005 (2)
2004 (2)
2003 (3)
2002 (2)
2001 (3)
2000 (1)
1999 (2)
1998 (1)
1996 (1)

Search

Sponsor content

842 result(s) found, displaying 321 to 330

FILPEGLA (Cipla Australia Pty Ltd)

1 August 2022

Prescription medicine registration

Active ingredients: Pegfilgrastim.
Trastucip and Tuzucip

29 July 2022

Prescription medicine decision summary

TGA decision: Trastucip and Tuzucip (trastuzumab) are approved to treat breast cancer.
TENVIR EMTRI 300/200 Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg tablet bottle pack (327876)

9 December 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TENVIR EMTRI 300/200 Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg tablet bottle pack.
CIPLA TENOFOVIR + EMTRICITABINE 300/200 Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg tablet bottle pack (327898)

9 December 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CIPLA TENOFOVIR + EMTRICITABINE 300/200 Tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg tablet bottle pack.
TRASTUCIP, TUZUCIP (Cipla Australia Pty Ltd)

7 July 2022

Prescription medicine registration

Active ingredients: Trastuzumab.
PHARMACOR CYPROTERONE 100 cyproterone acetate 100mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
PHARMACOR CYPROTERONE 50 cyproterone acetate 50mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - PRICELINE REFLUX RELIEF EXTRA STRENGTH ranitidine 300mg (as hydrochloride) capsule-shaped tablet blister strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - CIPLA RANITIDINE 300 ranitidine (as hydrochloride) 300 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - RANCIP 300 ranitidine (as hydrochloride) 300 mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd

Pages

First page
Previous page
…
Page 29
Page 30
Page 31
Page 32
Current page 33
Page 34
Page 35
Page 36
Page 37
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.